Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Management Inc (NQ: CGEM )

10.51 -0.05 (-0.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,215
Open 10.52
Bid (Size) 10.50 (270)
Ask (Size) 10.51 (48)
Prev. Close 10.56
Today's Range 10.30 - 10.68
52wk Range 7.300 - 15.89
Shares Outstanding 199,873,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cullinan Oncology, Inc.
Via Globe NewsWire

Performance

YTD
-1.59%
-1.59%
1 Month
-4.71%
-4.71%
3 Month
+2.64%
+2.64%
6 Month
-11.08%
-11.08%
1 Year
-13.99%
-13.99%

More News

Read More
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
From Cullinan Oncology, Inc.
Via Globe NewsWire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Via Talk Markets
5 Value Stocks In The Healthcare Sector
Via Benzinga
Insiders Buy Around $15M Of 2 Stocks
Via Benzinga
Short Volatility Alert: Cullinan Oncology
Via Benzinga
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via Globe NewsWire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
From Cullinan Oncology, Inc.
Via Globe NewsWire
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Cullinan Oncology, Inc.
Via Globe NewsWire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 200 Points; Dutch Bros Shares Plunge
Via Benzinga
90 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.